Introduction: treatment of malignancies poorly responsive to currently available antineoplastic therapy.
The decision whether to treat patients with malignancies that are poorly responsive to antineoplastic agents must be based on a number of important considerations, including the patients' performance status, co-morbid medical conditions, and the anticipated adverse effects of therapy. In appropriate patients, participation in experimental trials should be encouraged. In such circumstances, patients and their families must be given a realistic assessment of the limited or unknown benefits of treatment.